BMY re-submits Vanlev NDA

Bristol-Myers (BMY) re-submitted an NDA to the FDA for its Vanlev omapatrilat to treat hypertension. BMY said the NDA includes data from the Phase III 25,000-patient OCTAVE study comparing Vanlev to e...